The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.
A user shared their experience using RU58841, Minoxidil, and Finasteride for hair loss, noting good results but increased acne from RU58841. They plan to replace RU58841 with Finasteride while continuing Minoxidil.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
The conversation humorously discusses hair loss treatments, specifically mentioning the use of finasteride, minoxidil, and RU58841. The tone is satirical, with the user playfully referring to themselves as a "finasteride D-rider."
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.
The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.
User discusses hair regrowth using RU58841, minoxidil, and dutasteride. Many users praise the progress and ask about the treatments' effectiveness and side effects.
Adding RU58841 to a regimen of 2.5 mg dutasteride and 5 mg oral minoxidil for potential hair regrowth. Some users suggest a biopsy to determine the cause of hair loss, while others discuss the effectiveness and side effects of various treatments.
A user's 8-month progress using dutasteride, oral minoxidil, and 2 weeks of RU58841 to treat hair loss. The user is looking for feedback from others on their progress and experiences.
The user has been using RU58841 with minoxidil for hair loss, which helped but caused itchiness, and is considering increasing the dose and adding topical finasteride to the treatment. They are inquiring if they can mix RU58841 and finasteride into one solution with Stemoxydine or if they need separate solutions and which to apply first.
A user is seeking a UK source for a combined minoxidil and RU58841 solution that doesn't contain scalp-irritating ingredients. They specifically want a product without propylene glycol (PG).
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.
The conversation is about choosing an additional topical treatment for hair loss, with options being fluridil, topical spiro, or alfatradiol, alongside existing treatments like dutasteride, oral minoxidil, latanoprost, and RU58841. Opinions vary on the effectiveness of adding these topicals, with some suggesting RU58841 is sufficient.
Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
The conversation discusses the trustworthiness of Indian medications for hair loss, with some users mentioning they have purchased Minoxidil, finasteride, and RU58841 from India. Concerns include dosage and ingredient variations, but no harmful effects are noted.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
A 23-year-old male experienced no shedding with RU58841 but switched to oral finasteride due to heart concerns, resulting in increased hair shedding. He is considering adding minoxidil to his regimen, which currently includes finasteride, Nizoral shampoo, and microneedling.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.
The user experienced severe side effects when using topical Dutasteride and RU58841 together and is considering using them at different times of the day. They are seeking advice on whether this approach might reduce side effects.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
The conversation is about finding a trustworthy supplier for Pyrilutamide, a hair loss treatment. The user previously purchased RU58841 from Anagenic and is considering them for Pyrilutamide.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.
The conversation discusses hair loss treatments, specifically the use of anti-androgens like RU58841 and Pyrilutamide, which are expensive in India. Alternatives like spironolactone and concerns about the effectiveness of finasteride and dutasteride are also mentioned.